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Background: Cdk1 (cyclin-dependent kinase 1) is critical regulator of the G2-M checkpoint. Cyclin-dependent kinase
pathways are considered possible targets for cancer treatment; however, the prognostic role of Cdk1 in colorectal
cancer is still controversial. Therefore, we attempted to determine the impact of Cdk1 on the clinical outcome of
colorectal cancer patients to further identify its role in colorectal cancer.
Methods: Cdk1 immunoreactivity was analyzed by immunohistochemistry (IHC) in 164 cancer specimens from
primary colorectal cancer patients. The medium follow-up time after surgery was 3.7 years (range: 0.01 to 13.10 years).
The prognostic value of Cdk1 on overall survival was determined by Kaplan-Meier analysis and Cox proportional
hazard models.
Results: All samples displayed detectable Cdk1 expression with predominant location in the cytoplasm and nucleus.
A high Cdk1 nuclear/cytoplasmic (N/C) expression ratio was correlated with poor overall survival (5-year survival rate:
26.3% vs 46.9%, N/C ratio ≥1.5 vs N/C ratio <1.5, log-rank p = 0.027). Accordingly, a Cdk1 N/C expression ratio ≥1.5 was
identified as an independent risk factor by multivariate analysis (hazard ratio = 1.712, P = 0.039).
Conclusions: We suggest that Cdk1 N/C expression ratio determined by IHC staining could be an independent
prognostic marker for colorectal cancer.
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Colorectal cancer is one of the major causes of cancer
deaths in the world, and identifying reliable prognostic
markers is still an important issue for improving patients'
outcomes [1]. The clinical outcomes and treatment of
patients with colorectal cancer mainly depend on tumor
location and stage at diagnosis. Cancer metastasis, either
before or after surgical resection, leads to significantly
poor survival [2]. Successful metastasis requires that the
cancer cells enter the blood circulation, attach to the
endothelium, invade the target distant organs, and sub-
sequently form tumors [3,4]. Recently, we found that* Correspondence: 132540@cch.org.tw; 10159@cch.org.tw
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unless otherwise stated.cyclin-dependent kinase 1 (Cdk1) was overexpressed at
the RNA level in circulating tumor cells of colorectal
cancer when compared with control cells. This prompted
us to investigate the role of Cdk1 in the clinical outcome
of colorectal cancer patients.
Molecules involved in cell cycle regulation have been
attracting considerable attention as potential prognostic
and therapeutic cancer markers [5,6]. Cdks are key regu-
lators of cell cycle and RNA transcription [6] and cell
cycle defects in tumors are often mediated by altered Cdk
activities that result in unscheduled proliferation and
genomic and chromosomal instability [6]. Among Cdks,
Cdk1 is sufficient for driving the cell cycle in all cell types,
identifying its master role in regulating cell proliferation
[6]. Cdk1, formerly called cell division control protein 2
(Cdc2), interacts with cyclin B1 to form an active hetero-
dimer that drives cells through mitosis [7,8].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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marker in non-small cell lung cancer, colon cancer, and
breast cancer [9-15]. However, its prognostic role is still
controversial and more evidence is needed for further
clinical application. A high specific activity of Cdk1
measured on 254 fresh-frozen tumor samples from
stage II colon cancer patients was associated with short
distant-metastasis-free intervals and poor prognosis [14].
An association between high specific activity of Cdk1 and
microsatellite-stable tumors provided molecular evidence
to further support this finding [14]. However, Meyer and
colleagues revealed that patients with an ‘absent’ score for
Cdk1 had poor cancer-related 5-year survival, indicating
the absence of Cdk1 to be an independent prognostic
marker in stage UICC II colon carcinoma [15]. These
conflicting results led us to investigate the role of Cdk1 in
our patient population.
Interestingly, Zhang and colleagues found that Cdk1
was highly expressed in non-small cell lung cancer tumor
tissues, but its loss from the cytoplasm could predict poor
prognosis [13]. This finding prompted us to consider that
the prognostic role of Cdk1 might depend on its expres-
sion in the nucleus and cytoplasm. The aim of the present
study was to clarify the prognostic implications of Cdk1




In this study, we enrolled de-linked tissue specimens
from 164 colorectal cancer patients and the written and
oral consent was not obtained. Tissue collection was
retrospective and all tissue was obtained from hospitals
archives. The Institutional Review Board waived the
need for consent. This study was approved by the Insti-
tutional Review Board and the Ethics Committee of the
Changhua Christian Hospital, Changhua, Taiwan (IRB
no. 121008).
Study subjects
This study enrolled 164 colorectal cancer patients. The
tumor tissues were collected from patients with confirmed
histological diagnosis at Changhua Christian Hospital
between 1997 and 2000. No patient underwent preopera-
tive radiotherapy, chemotherapy, or any other treatment.
Cancers were staged according to the AJCC Colon Cancer
Staging, 7th edition (2009). Clinical data including sex, age,
stage, T, N, and M stages, and follow-up information were
obtained from medical records and the cancer registry.
Immunohistochemistry staining and evaluation of Cdk1
immunoreactivity
Immunohistochemistry (IHC) staining was performed at
the Department of Surgical Pathology, Changhua ChristianHospital, as previously described [16,17]. IHC analyses
were performed on tissue microarray sections (4 μm) of
formalin-fixed, paraffin-embedded, pre-chemotherapy pri-
mary colorectal tumors. The sections were placed on
coated slides, washed with xylene to remove the paraffin,
and rehydrated through serial dilutions of alcohol,
followed by washings with a solution of phosphate
buffered saline, PBS (pH = 7.2). Endogenous peroxidase
activity was blocked with 3% H2O2. Antigen retrieval
was performed by boiling in citrate buffer (10 mM) for
20 min. After incubation with the anti-human Cdk1
antibody (Cdc2 p34 antibody, 1:180 dilution; sc-166135,
Santa Cruz Biotechnology) for 20 min at room temp-
erature and thorough washing (three times with PBS).
The immunoreaction was visualized using polymer-based
MACH4 DAB Detection Kit (Biocare Medical) according
to the manufacturer’s instructions to obtain optimal
immunoreactivity and least background artifact. The
slides were incubated with a horseradish peroxidase
(HRP)/Fab polymer conjugate for another 30 min. The
sites of peroxidase activity were visualized using 3,3'-
diamino-benzidine tetrahydrochloride as the substrate
for 300 seconds and hematoxylin as the counterstain.
Pathologically verified normal colon specimens were used
as positive control (Additional file 1: Figure S1). PBS was
used instead of primary antibodies as a negative control
(Additional file 1: Figure S1). Immunoreactivity scores
were analyzed by pathologists using scores defined as
previously described [17,18]. In brief, immunoreactivity
scores were defined as the cell staining intensity (0 = nil;
1 = weak; 2 =moderate; and 3 = strong) multiplied by the
percentage of stained cells (0–100%), leading to scores
from 0 to 300. Cdk1 immunoexpression was assessed
semiquantitatively by 2 pathologists (YML and CJC), who
independently scored coded sections based on the staining
score without knowledge of clinical and follow-up infor-
mation. A final agreement was obtained for each score
by using a multiheaded microscope (Olympus BX51 10
headed microscopes).
Statistical analysis
The Student t test, Fisher's exact test and the χ2 test
were applied for continuous or discrete data analysis.
The associations between the Cdk1 and patient survival
were estimated using the Kaplan–Meier method and
assessed using the log-rank test. Potential confounders
were adjusted by Cox regression models, with the Cdk1
fitted as indicator variables. Overall survival time was
defined as the interval between the date of surgery and
the date of last follow-up or death. All statistical analyses
were conducted using the SPSS statistical software pro-
gram (version 15.0) (SPSS, Inc., Chicago, IL). All statis-
tical tests were 2-sided, and the values of P <0.050 were
considered statistically significant.
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Cdk1 is expressed in the majority of colorectal specimen
and locates to both the cytoplasm and nucleus
We verified the role of Cdk1 in clinical outcome of colo-
rectal patients by recruiting 164 patients with primary
tumors. The clinicopathological characteristics of the
study subjects are listed in Table 1. The mean age was
64.5 ± 12.9 years (mean ± SD) and the gender ratio was
0.72: 1.00 (female: male). In total, 22 patients had stage
I tumors, 64 patients had stage II tumors, 50 patients
had stage III tumors, and 28 patients had stage IV
tumors. Twenty-seven patients had distant metastasis
at diagnosis.
Cdk1 expression was evaluated by IHC staining of
tissue arrays. Figure 1 shows a representative immuno-
staining of Cdk1 in a colorectal cancer specimen. The
Cdk1 expression in the cytoplasm and nucleus were
scored separately by pathologists. All specimens had Cdk1
expression in cytoplasm and only 2 cases had no Cdk1
expression in the nucleus (1.2%). The median Cdk1 ex-
pression score was 200 for cytoplasm staining and 180
for nucleus staining and we used the median value as
cut-off point for further analysis. As shown in Table 1,
Cdk1 expression in the cytoplasm and nucleus had no





Age (year) 64.1 ± 12.4 65.2 ± 13.9
Gender
Female 69 37 (53.6) 32 (46.4)
Male 95 65 (68.4) 30 (31.6)
Stage
I 22 11 (50.0) 11 (50.0)
II 64 42 (65.6) 22 (34.4)
III 50 31 (62.0) 19 (38.0)
IV 28 18 (64.3) 10 (35.7)
T value
1 5 3 (60.0) 2 (40.0)
2 20 9 (45.0) 11 (55.0)
3 124 76 (61.3) 48 (38.7)
4 15 14 (93.3) 1 (6.7)
N value
0 94 58 (61.7) 36 (38.3)
1 63 37 (58.7) 26 (41.3)
2 7 7 (100.0) 0 (0.0)
M value
0 137 84 (61.3) 53 (38.7)
1 27 18 (66.7) 9 (33.3)value, except that the patients with low cytoplasmic Cdk1
expression (score ≦200) were prone to have an ad-
vanced T value (p = 0.033). Overall, Cdk1 expression in
the cytoplasm and nucleus was not related to clinical
parameters except cytoplasm Cdk1 expression in T stage
in our study population.
The prognostic role of Cdk1 expression in the cytoplasm
and nucleus of colorectal patients
We further verified the prognostic role of Cdk1 expression
in colorectal patients. Overall survival data were collected
and no data were missing among 164 patients. The mean
and median follow-up times after surgery were 5.1 and
3.7 years (range from 0.01 to 13.10 years), respectively.
The 5-year survival rate was 44.5%. During the survey,
138 patients died. We evaluated the possible correlation
of Cdk1 expression and clinical outcome by grouping
patients into four subgroups according to the quartile and
median values of Cdk1 expression in the cytoplasm and
nucleus (cut-off points were 180, 200, and 285 for the
cytoplasm; and 150, 180, and 255 for the nucleus).
Patients' survival was estimated using the Kaplan-Meier
method and Cdk1 expression in cytoplasm and nucleus
was not a significant prognostic marker in our study
(log-rank test: p = 0.565 for cytoplasm expression andion with clinical parameters in colorectal cancer patients
p value Nucleus Cdk1 expression p value
≦180 >180
0.582 64.5 ± 13.3 64.6 ± 12.7 0.948
0.054 33 (47.8) 36 (52.2) 0.940
46 (48.4) 49 (51.6)
0.623 10 (45.5) 12 (54.5) 0.241
33 (51.6) 31 (48.4)
19 (38.0) 31 (62.0)
17 (60.7) 11 (39.3)
0.033 4 (80.0) 1 (20.0) 0.180
6 (30.0) 14 (70.0)
61 (49.2) 63 (50.8)
8 (53.3) 7 (46.7)
0.101 46 (48.9) 48 (51.1) 0.096
27 (42.9) 36 (57.1)
6 (85.7) 1 (14.3)
0.600 63 (46.0) 74 (54.0) 0.207
16 (59.3) 11 (40.7)
Figure 1 Representative immunostaining of Cdk1 in colorectal cancer in tissue arrays according to the N/C ratio. N/C ratio of Cdk1 were
(A) 0.00-0.49; (B) 0.50-0.99; (C) 1.00-1.49; (D) ≥1.5. (Magnification: 200×).
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Figure S2). We further analyzed the prognostic value by
Cox regression model, as shown in Additional file 3:
Table S1. Neither cytoplasmic nor nuclear Cdk1 expres-
sion could predict clinical outcome in 5-year survival, uni-
variate analysis, and multivariate analysis. Thus, we found
no prognostic role of Cdk1 expression when examined
separately in the cytoplasm and nucleus.
High nuclear/cytoplasmic ratio of Cdk1 expression
predicts poor prognosis in colorectal cancer
We considered the protein dynamics of posttranslational
regulation by combining the cytoplasmic and nuclear
expression of Cdk1 as a N/C ratio for further analysis
[19]. The N/C ratio ranged from 0.0 to 24.0 (mean ± SD:
1.3 ± 2.2; medium: 0.9). The cut-off point (N/C ratio:
1.5) was determined according to the clinical outcome
observed in different subgroups (Figure 2A), as shown in
Figure 2B. Table 2 shows the relationships of the N/Cratio with clinical parameters. Patients with tumors with
N/C ratios ≥1.5 had a significantly advanced T value
compared with those with N/C ratios <1.5 (p = 0.004,
Table 2). However, no significant difference was noted
between patients with high and low N/C ratios with
respect to tumor stage, N value, or M value.
We further analyzed the prognostic impact of the N/C
ratio in our population. We grouped the N/C ratios into
4 subgroups consisting of the following values: 0.00-0.49;
0.50-0.99; 1.00-1.49; ≥1.50. Figure 2A shows patient sur-
vival estimated using the Kaplan-Meier method; patients
with N/C ratios ≥1.5 had the poorest survival of all
subgroups (p = 0.134). We estimated the prognostic sig-
nificance of this N/C ratio, we compared the clinical out-
come of patients with N/C ratios ≥1.5 and <1.5. Patients
with N/C ratios ≥1.5 had significantly poorer survival
compared with those with N/C ratios <1.5 (Figure 2B).
The 5-year survival of patients with N/C ratios ≥1.5 was
26.3% while it was 46.9% in those with N/C ratios <1.5
Figure 2 A high Cdk1 N/C ratio was correlated with poor overall survival. Kaplan-Meier actuarial analysis of overall survival according to (A) N/C
ratio subgroups and (B) N/C ratio cut by 1.5 of Cdk1 immunostaining expression in colorectal cancer patients. The case number was 18, 101, 26, and
19 according to N/C ratio subgroups, respectively.
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gression model (Tables 3 and 4). We adjusted age, gender,
stage, and N/C ratio in multivariate analysis (Table 4). In
our study population, patients with advanced stage cancer
had significantly poorer prognosis compared with thoseTable 2 Relationships of nucleus/cytoplasm ratio (N/C




Cdk1 N/C ratio p value
<1.5 ≥1.5
Age (year) 65.3 ± 12.6 58.8 ± 14.5 0.078
Gender
Female 69 64 (92.8) 5 (7.2) 0.139
Male 95 81 (85.3) 14 (14.7)
Stage
I 22 20 (90.9) 2 (9.1) 0.975
II 64 56 (87.5) 8 (12.5)
III 50 44 (88.0) 6 (12.0)
IV 28 25 (89.3) 3 (10.7)
T value
1 5 5 (100.0) 0 (0.0) 0.004
2 20 18 (90.0) 2 (10.0)
3 124 113 (91.1) 11 (8.9)
4 15 9 (60.0) 6 (40.0)
N value
0 94 82 (87.2) 12 (12.8) 0.803
1 63 57 (90.5) 6 (9.5)
2 7 6 (85.7) 1 (14.3)
M value
0 134 118 (88.1) 16 (11.9) 0.764
1 30 27 (90.0) 3 (10.0)with early stage disease (HR = 1.783, 95% CI = 1.071-2.966,
P = 0.026 for univariate analysis; HR = 1.712, 95% CI =
1.027-2.853, P = 0.039 for multivariate analysis, Tables 3
and 4). As expected, significantly poorer clinical outcome
was found for patients with N/C ratios ≥1.5 (HR = 1.733,
95% CI = 1.051-2.856, P = 0.031 for univariate analysis;
HR = 1.712, 95% CI = 1.027-2.853, P = 0.039 for multivari-
ate analysis, Tables 3 and 4). This is evidence that the
Cdk1 N/C expression ratio could be an independent prog-
nostic marker for colorectal cancer.
Discussion
Cdk1 is a catalytic subunit that promotes the M-phase
process and is essential for G1/S and G2/M phase tran-
sitions during cell proliferation [6,20]. In addition, cyclin
B-Cdk1 has been implicated in cell survival during the
mitotic checkpoint (also known as the spindle assembly
checkpoint) [21]. Cancer cells with high Cdk1 expression
appear to have greater cell proliferation capability, so
that patients with this type of tumor might have poor
outcomes [5]. Thus, the use of small-molecule Cdk1
inhibitors could improve arrest at the G2-M boundary
and prevent the entry of cancer cells into mitosis, thereby
resulting in enhancement of apoptosis and tumor regres-
sion [21,22]. These results suggest that Cdk1 might be
more than just a therapeutic target but might serve as a
predictor of the prognosis of cancer patients.
Cdk1 has been identified as a clinically useful prognostic
marker in non-small cell lung cancer, colon cancer, and
breast cancer [9-15]. High Cdk1 expression was associated
with poor prognosis for cancer relapse, especially in node-
negative breast cancer patients [9]. Non-small cell lung
cancer patients with high Cdk1 expression levels also had
poorer overall and recurrence survival than those with
lower Cdk1 expression [12]. Interestingly, Zhang and col-
leagues found that although Cdk1 was highly expressed in
Table 3 Univariate analysis of the influence of various parameters on overall survival in colon cancer patients
Parameter Category Overall survival
5-year survival (%) HR 95% CI p value
Age, y ≥65/<65 43.9/45.7 1.261 0.899-1.769 0.179
Gender Male/Female 44.8/44.4 1.134 0.811-1.586 0.463
Stage II + III + IV/I 40.0/73.9 1.783 1.071-2.966 0.026
Cdk1 N/C ratio ≥1.5/<1.5 26.3/46.9 1.733 1.051-2.856 0.031
Sung et al. BMC Cancer 2014, 14:951 Page 6 of 7
http://www.biomedcentral.com/1471-2407/14/951non-small cell lung cancer tissues, its loss from the cyto-
plasm predicted poor survival and conferred resistance to
chemotherapy both in vivo and in vitro [13]. This result
suggested that Cdk1 might have different biological roles
depending on its expression in the nucleus and cytoplasm
and this might give rise to different clinical outcomes.
The prognostic role of Cdk1 in colon cancer is still
controversial. For example, Zeestraten and colleagues
identified that Cdk1 but not Cdk2 can predict distant-
metastasis-free survival and cause-specific survival in
stage II colon cancer [14]. Patients with high Cdk1 specific
activity had significantly shorter distant-metastasis-free
intervals compared with those with low Cdk1 specific
activity [14]. Although the Cdk1 expression had no
association with ki-67 mitotic index, the prognostic results
were further supported by the enhanced expression of
Cdk1 in microsatellite-stable tumors [14]. These findings
were further supported by poor prognosis of colon cancer
patients with microsatellite-stable tumors [23]. However,
Meyer and colleagues reported that the absence of Cdk1
expression by immunohistochemistry staining of tissue
arrays was associated with significantly poor cancer-
related 5-year survival in stage UICC II colon carcin-
oma [15]. This study included patients with stage UICC
II, III, and IV, and the prognostic role of Cdk1 in
cancer-related 5-year survival risk was only observed in
stage II but not in the other stages or when all stages
were combined [15]. These conflicting results prompted
us to investigate the prognostic role of Cdk1 in our patient
population.
Considering the report that loss of cytoplasmic Cdk1
expression predicts poor clinical outcome in non-small
cell lung cancer patients, we scored Cdk1 expression
separately in the nucleus and cytoplasm [13]. In our
cases, all specimens had Cdk1 expression in cytoplasmTable 4 Multivariate analysis of the influence of various para
Parameter Category Overall survival
5-year survival (%
Age, y ≥65/<65 43.9/45.7
Gender Male/Female 44.8/44.4
Stage II + III + IV/I 40.0/73.9
Cdk1 N/C ratio ≥1.5/<1.5 26.3/46.9
Adjusted for age, gender and stage.and only 2 cases had no Cdk1 expression in nucleus. No
Cdk1 expression was found in adjacent normal tissue. Cox
regression analysis of our data indicated no significant
association of tumor Cdk1 expression in the nucleus
and cytoplasm with clinical outcome (Additional file 3:
Table S1). Kaplan–Meier analysis gave a similar result
(Additional file 2: Figure S2).
The nuclear translocation of cyclin B/CDC2 complexes,
which is required for the initiation of mitosis, is inhibited
by 14-3-3σ. The 14-3-3 σ gene undergoes frequent epigen-
etic silencing in several types of cancer due to aberrant
CpG methylation of specific promoters. Therefore we
combined cytoplasmic and nuclear expression of Cdk1
as the N/C ratio for further analysis [19]. Interestingly,
patients with high N/C ratios had lower 5-year survival
rates than those with low N/C ratios (Table 3). Multi-
variate analysis confirmed the independent prognostic
role of Cdk1 when grouped by N/C ratio (Table 4). This
might reflect the poor prognosis of non-small cell lung
cancer patients with tumors that lost cytoplasm Cdk1
expression [13].
The present study reveals a novel strategy for the use
of the Cdk1 N/C ratio rather than the Cdk1 expression
in the entire cancer cell for predicting prognosis of colon
cancer patients. Our results suggested that Cdk1 might
have a different prognostic role depending on the cancer
type and the location of Cdk1 expression.Conclusions
In this study, we found no prognostic role of Cdk1 ex-
pression in the cytoplasm and nucleus, respectively.
However, Cdk1 N/C expression ratio determined by IHC
staining could be an independent prognostic marker for
colorectal cancer.meters on overall survival in colon cancer patients
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Additional file 1: Figure S1. Positive and negative control of Cdk1 IHC
staining. (A) Normal colon tissue was used as the positive control and
showed weak Cdk1 immunostain. Also seen was some Cdk1 positive
lymphocytes infiltration in the colon tissues. (B) PBS was used instead of
primary antibodies as a negative control. The same normal colon tissue
core showed no Cdk1 immunoreactivity including colon glands and
lymphocytes. (Magnification: 200×).
Additional file 2: Figure S2. Kaplan-Meier actuarial analysis of overall
survival according to Cdk1 expression in (A) cytoplasm and (B) nucleus
in colorectal cancer patients.
Additional file 3: Table S1. Univariate and multivariate analysis of
cytoplasm and nucleus Cdk1 expression on overall survival in colorectal
cancer patients.
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